Literature DB >> 27057425

Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia.

Tsukasa Seya1, Yohei Takeda1, Misako Matsumoto1.   

Abstract

Here, we introduce a double-stranded RNA mimic that is chemically synthesized to exclusively stimulate toll-like receptor 3 (TLR3). This function-defined TLR3 ligand, named ARNAX, acts as an adjuvant to induce antitumor CTL and NK without significant cytokinemia in mice, and thus superior to polyI:C for therapeutic vaccine immunotherapy against tumor.

Entities:  

Keywords:  Antitumor CTL; Priming-phase adjuvant; no cytokine toxicity; tumor remission

Year:  2015        PMID： 27057425      PMCID： PMC4801468          DOI： 10.1080/2162402X.2015.1043506

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Signals required for programming effector and memory development by CD8+ T cells.

Authors:  Matthew F Mescher; Julie M Curtsinger; Pujya Agarwal; Kerry A Casey; Michael Gerner; Christopher D Hammerbeck; Flavia Popescu; Zhengguo Xiao
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

2.  Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo.

Authors:  Misako Matsumoto; Megumi Tatematsu; Fumiko Nishikawa; Masahiro Azuma; Noriko Ishii; Akiko Morii-Sakai; Hiroaki Shime; Tsukasa Seya
Journal:  Nat Commun       Date:  2015-02-18       Impact factor: 14.919

Review 3.  Innate immune recognition of cancer.

Authors:  Seng-Ryong Woo; Leticia Corrales; Thomas F Gajewski
Journal:  Annu Rev Immunol       Date:  2015-01-22       Impact factor: 28.527

4.  Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells.

Authors:  Takashi Akazawa; Takashi Ebihara; Manabu Okuno; Yu Okuda; Masashi Shingai; Kunio Tsujimura; Toshitada Takahashi; Masahito Ikawa; Masaru Okabe; Norimitsu Inoue; Miki Okamoto-Tanaka; Hiroyoshi Ishizaki; Jun Miyoshi; Misako Matsumoto; Tsukasa Seya
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-26       Impact factor: 11.205

Review 5.  Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer.

Authors:  Tsukasa Seya; Masahiro Azuma; Misako Matsumoto
Journal:  Expert Opin Ther Targets       Date:  2013-02-18       Impact factor: 6.902

6.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

7.  TLR3/TICAM-1 signaling in tumor cell RIP3-dependent necroptosis.

Authors:  Tsukasa Seya; Hiroaki Shime; Hiromi Takaki; Masahiro Azuma; Hiroyuki Oshiumi; Misako Matsumoto
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

8.  Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

9.  Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cells.

Authors:  Masahiro Azuma; Takashi Ebihara; Hiroyuki Oshiumi; Misako Matsumoto; Tsukasa Seya
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

10.  Trial Watch: Toll-like receptor agonists in oncological indications.

Authors:  Fernando Aranda; Erika Vacchelli; Florine Obrist; Alexander Eggermont; Jérôme Galon; Catherine Sautès-Fridman; Isabelle Cremer; Jan Henrik Ter Meulen; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-08-01       Impact factor: 8.110
  10 in total
  5 in total

Review 1.  An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives.

Authors:  Alessio Facciolà; Giuseppa Visalli; Antonio Laganà; Angela Di Pietro
Journal:  Vaccines (Basel)       Date:  2022-05-22

Review 2.  Signal-transducing innate receptors in tumor immunity.

Authors:  Sho Hangai; Yoshitaka Kimura; Tadatsugu Taniguchi; Hideyuki Yanai
Journal:  Cancer Sci       Date:  2021-05-01       Impact factor: 6.716

Review 3.  Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy.

Authors:  Misako Matsumoto; Yohei Takeda; Megumi Tatematsu; Tsukasa Seya
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

4.  Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis.

Authors:  Lugain Alkurdi; François Virard; Béatrice Vanbervliet; Kathrin Weber; Florent Toscano; Marc Bonnin; Nolwenn Le Stang; Sylvie Lantuejoul; Olivier Micheau; Toufic Renno; Serge Lebecque; Yann Estornes
Journal:  Cell Death Dis       Date:  2018-08-29       Impact factor: 8.469

Review 5.  Trial watch: TLR3 agonists in cancer therapy.

Authors:  Julie Le Naour; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2020-06-02       Impact factor: 8.110
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.